University of Ioannina is a university lying in the plains 5 km southwest of Ioannina, Greece. The campus is linked to the town by Greek National Road 5. It now hosts over 20,000 students in 17 faculties . The university was founded in 1964, as a charter of the Aristotle University of Thessaloniki and became an independent university in 1970. University of Ioannina is one of the leading academic institutions in Greece. Wikipedia.
Roukos D.H.,University of Ioannina |
Roukos D.H.,Systems Biology Unit of Biomedical Research Foundation of the Academy of Athens BRFAA
Drug Discovery Today | Year: 2016
The unprecedented potential of standard and new next-generation sequencing applications and methods to explore cancer genome evolution and tumor heterogeneity as well as transcription networks in time and space shapes the development of next-generation therapeutics. However, biomedical and pharmaceutical research for overcoming heterogeneity-based therapeutic resistance is at an important crossroads. Focus on linear transcription-based drug development targeting dynamics of simple intrapatient structured genome diversity represents a realistic medium-term goal. By contrast, the discovery of nonlinear transcription drugs for targeting structural and functional genome and transcriptome heterogeneity represents a long-term rational strategy. This review compares effectiveness, challenges and expectations between linear and nonlinear drugs targeting simple intrapatient variation and aberrant transcriptional biocircuits, respectively. © 2016 Elsevier Ltd. All rights reserved.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.3.3-1 | Award Amount: 7.60M | Year: 2013
The CREDITS4HEALTH projects main goal is to develop a person centric approach based on the credits for health concept to reduce sedentary behavior and enhance the level of physical activity and healthy dietary styles in people living in Euro-Mediterranean Countries. The concept of credits is simple and effective: this means that each participant will earn credits from his local, regional or national Health Authority on the basis of his/her participation and involvement in the achievement of an healthy life-style, and his/her attitude to sponsor this philosophy in his community. The CREDITS4HEALTH vision is therefore to have people directly acting for their health and well being, operating on three fundamental levers to enhance the quality of their lives, through the reduction of sedentary behavior, the active participation to the social life and the adoption of an healthier diet. The CREDITS4HEALTH approach is virtuous and straightforward: 1)First, we will define personalised algorithms containing dietary and physical activity prescriptions, taking into account the medical, psychological, social, and economic background of each person; 2) Once screened by the local Credits4Health Committee, the participant receives an electronic card, which enables him to track his compliance to the regime through a dedicated web based platform; 3)With his electronic card, the participant also gets access to a full range of suppliers which offer him goods for fulfilling his health-related objectives;4)Suppliers must be certified by the local authority, according to a specified set of requirements and they must certify the products they intend to commercialise for this initiative;5)Participants gain credits as far as they comply with their daily, weekly and monthly goals; they are also subject to a six monthly mandatory assessment performed by the Credits4Health Committee, in which the algorithm can be modified and fine-tuned to the needs of the participant.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: OCEAN 2013.1 | Award Amount: 7.59M | Year: 2013
Early warning systems that can provide extreme sensitivity with exquisite selectivity are required to assess chemical contamination of estuarine and coastal areas. SEA-on-a-CHIP aims to develop a miniaturized, autonomous, remote and flexible immuno-sensor platform based on a fully integrated array of micro/nano-electrodes and a microfluidic system in a lab-on-a-chip configuration combined with electrochemical detection for real time analysis of marine waters in multi-stressor conditions. This system will be developed for a concrete application in aquaculture facilities, including the rapid assessment of 8 selected contaminants from 5 groups of compounds that affect aquaculture production (compounds which are toxic, bioaccumulative, endocrine disruptors) and also those produced by this industry that affect environment and human health (antibiotics and pesticides), but it is easy adaptable to other target compounds or other situations like coastal waters contamination analysis. Each device will be able to perform 8 simultaneous measures in duplicates and it will be build in order to work with one-month autonomy and measuring in real time at least once per hour. As many devices as needed could be connected simultaneously to the same platform resulting in a very flexible and inexpensive system. Sensitivity for Sea-Water analysis is guaranteed thanks to the use of gold microelectrodes arrays with metalocarborane doped functional polypyrrol. Thank to the use of MEMS and microlectrodes in flexible polymeric substrates the costs of production will be reduced. The units will be tested throughout the lifetime of the project and calibrated to state-of-the-art of chemical analytics: first in laboratory studies, second under artificial ecosystems and finally during 3 field experiments in the installation of 2 aquaculture SME facilities. The last test phase will be performed in a way that will include dissemination of the findings with a clear view of commercializing the devices.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.4-1 | Award Amount: 11.55M | Year: 2013
The target of the Smartonics project is the development of Pilot lines that will combine smart technologies with smart nanomaterials for the precision synthesis of Organic Electronic (OE) devices. The Smartonics objectives are: 1.Development of smart Nanomaterials for OEs (polymer & small molecule films, plasmonic NPs and super-barriers) by process and computational modeling optimization. 2.Development of smart Technologies (r2r printing and OVPD machines combined with precision sensing & laser tools and processes). 3.Integration of Nanomaterials & Technologies in Pilot lines for precision synthesis of Nanomaterials & OE devices, optimization, demonstration and evaluation for Industrial applications. Smartonics will develop three Pilot lines: a) OVPD Pilot line equipped with in-line optical sensing tools, b) r2r printing Pilot line, which will combine optical sensing and laser processing tools, and c) s2s Pilot line for the precision fabrication of OE devices (e.g. OLEDs, sensors from state-of-the-art Nanomaterials) and for the evaluation of encapsulation of these devices. The above will be up-scaled in Industrial processes. More specifically: - The parameters for small molecule OPVs will be up-scaled to Industrial scale OVPD machine. - The process parameters for r2r OPVs will be up-scaled and demonstrated in r2r printing machines. - The advances and precision in the synthesis of nanomaterials by the optical sensing tool will be evaluated for flexible displays. - The advances for the r2r printing process will be evaluated for large-scale production of OPVs. - The flexible OPVs will be validated and implemented in automotives applications. All the above are consistent with the topic NMP.2012.1.4-1 since the the targets of project are including the development of Pilot lines that will be combined with production machines (gas (transport and printing), precision and fabrication tools and processes for the precision synthesis of Nanomaterials and OEs.
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2013-1 | Award Amount: 1.27M | Year: 2014
Large public infrastructure facilities around the world like dams, cooling towers and bridges use cement as the main building material. Although made from a durable material many of these large assets have begun to age and are in need of periodic inspection to ensure their integrity. Current inspection routine involves setting up scaffolds that have to be moved around for personnel to reach to the whole of the surface. The VORTEXSCAN proposal seeks to develop a vortex robot that will autonomously navigate the vertical surfaces of such structures while deploying a combination of non destructive inspection techniques. Air suction through a nozzle of a specific geometry will create a vortex and initiate a force that attaches the robot to a vertical surface while its wheels move it around. Novel phased array Ground Penetrating Radar (GPR) will be one of the two NDT equipment carried by the robot. Low frequency ultrasonics will also be deployed and an innovative fusion of data from the two techniques will be performed. The fusion will diminish the drawbacks of each technique and create an accurate representation of the underlying material and its defects. VORTEXSCAN will create a system that can rapidly and economically inspect large vertical concrete structures saving huge amounts currently spent during the manual periodic inspections. The system will target EUs electrical power industry structures such nuclear reactor containment, dams and cooling towers as a large number of these infrastructure types are beginning to age; some of them having been built nearly a century ago.
Christou G.A.,University of Ioannina
The Journal of endocrinology | Year: 2014
Adiponectin is secreted by the adipose tissue and is downregulated in states of obesity and insulin resistance. There is a growing body of evidence indicating that adiponectin has renoprotective effects and protects against the development of albuminuria in rodent experiments. Adiponectin crossing the glomerular filtration barrier possibly inhibits inflammation, fibrosis and oxidative stress in kidneys through activation of AMP-activated protein kinase. Moreover, microalbuminuria is a well established early sign of progressive cardiovascular and renal disease, even in subjects with preserved glomerular filtration rate. Studies investigating the relationship between serum adiponectin levels and urinary albumin excretion rate (UAE) have yielded conflicting data and the mechanisms underlying the interplay between adiponectin and albuminuria remain to be elucidated. This article constitutes a critical review attempting to clarify any remaining confusion about this matter. Furthermore, this article examines the clinical significance of adiponectin-albuminuria interplay, suggesting that adiponectin is possibly involved in the development of albuminuria that is associated with obesity, diabetes and cardiovascular disease and may mediate, at least in part, the actions of medical treatments that influence UAE, such as angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, thiazolidinediones, fenofibrate and diet. Further studies to investigate more thoroughly the renoprotective role of adiponectin in the human setting should be carefully planned, focusing on causality and the possible influence of adiponectin on the development of albuminuria in specific clinical settings.
Tsipis A.C.,University of Ioannina
Coordination Chemistry Reviews | Year: 2014
An overview of recent progress in DFT application to coordination chemistry is presented. Some recent applications that best illustrate the promise of DFT in a number of very active areas of coordination chemistry, such as catalysis (mechanistic studies), bonding (electronic and bonding character) electronic spectroscopy (absorption and emission spectra) and heavy-nucleus NMR spectroscopy are reviewed. Particular emphasis was given to the practical aspects that may be interesting for experimentalists that wish to employ DFT alongside to their experimental work. General instructions of how to select the proper DFT computational protocol for a particular study are outlined. © 2014 Elsevier B.V.
Roukos D.H.,University of Ioannina
Pharmacogenomics Journal | Year: 2011
Life diversity can now be clearly explored with the next-generation DNA sequencing technology, allowing the discovery of genetic variants among individuals, patients and tumors. However, beyond causal mutations catalog completion, systems medicine is essential to link genotype to phenotypic cancer diversity towards personalized medicine. Despite advances with traditional single genes molecular research, including rare mutations in BRCA1/2 and CDH1 for primary prevention and trastuzumab for treating HER2-overexpressing breast and gastric tumors, overall, treatment failure and death rates are still alarmingly high. Revolution in sequencing reveals that, now both a huge number and widespread variability of driver mutations, including single-nucleotide polymorphisms, genomic rearrangements and copy-number changes involved in breast cancer development. All these genetic alterations result in a heterogeneous deregulation of signaling pathways, including EGFR, HER2, VEGF, Wnt/Notch, TGF and others.Cancer initiation, progression and metastases are driven by complex molecular networks rather than linear genotype-phenotype relationship. Therefore, clinical expectations by traditional molecular research strategies targeting single genes and single signaling pathways are likely minimal. This review discusses the necessity of molecular networks modeling to understand complex gene-gene, protein-protein and gene-environment interactions. Moreover, the potential of systems clinico-biological approaches to predict intracellular signaling pathways components networks and cancer heterogeneous cells within an individual tumor is described. A flowchart specific for three steps in cancer evolution separately tumorigenesis, early-stage and advanced-stage breast cancer is presented. Using reverse engineering starting with the integration of available established clinical, environmental, treatment and oncological outcomes (survival and death) data and then the still incomplete but progressively accumulating genotypic data into computational networks modeling may lead to bionetworks-based discovery of robust biomarkers and highly effective cancer drugs targets. © 2011 Macmillan Publishers Limited. All rights reserved.
Evangelou E.,University of Ioannina |
Ioannidis J.P.A.,Stanford University
Nature Reviews Genetics | Year: 2013
Meta-analysis of genome-wide association studies (GWASs) has become a popular method for discovering genetic risk variants. Here, we overview both widely applied and newer statistical methods for GWAS meta-analysis, including issues of interpretation and assessment of sources of heterogeneity. We also discuss extensions of these meta-analysis methods to complex data. Where possible, we provide guidelines for researchers who are planning to use these methods. Furthermore, we address special issues that may arise for meta-analysis of sequencing data and rare variants. Finally, we discuss challenges and solutions surrounding the goals of making meta-analysis data publicly available and building powerful consortia. © 2013 Macmillan Publishers Limited.
Pavlidis N.,University of Ioannina |
Pentheroudakis G.,University of Ioannina
The Lancet | Year: 2012
Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. Diagnostic approaches to identify the primary site include detailed histopathological examination with specific immunohistochemistry and radiological assessment. Gene-profiling microarray diagnosis has high sensitivity, but further prospective study is necessary to establish whether patients' outcomes are improved by its clinical use. Metastatic adenocarcinoma is the most common CUP histopathology (80). CUP patients are divided into subsets of favourable (20) and unfavourable (80) prognosis. Favourable subsets are mostly given locoregional treatment or systemic platinum-based chemotherapy. Responses and survival are similar to those of patients with relevant known primary tumours. Patients in unfavourable subsets are treated with empirical chemotherapy based on combination regimens of platinum or taxane, but responses and survival are generally poor. © 2012 Elsevier Ltd.